Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Development of Combination Therapies The development of combination therapies presents a significant opportunity in the GLP-1 targeted peptide weight loss drugs market by enhancing treatment efficacy and expanding therapeutic options
Study Design and Population The trial enrolled 445 participants across three groups in a 1:1:1 randomization: Retatrutide 9mg group: 148 participants Retatrutide 12mg group: 149 participants Placebo group: 148 participants Participants had an average baseline weight of 112.7 kg (248.5 lbs) and a mean BMI of 40.4 kg/m
Every treatment plan is tailored individually to the lifestyle and preference of the client in order to optimize results and minimize side effects
10.1210/en.2018-00004 8 BandayM
US$ 25.27
US$ 29.20
US$ 27.83
